Literature DB >> 16846401

Neurohormones and heart failure: the importance of aldosterone.

K Odedra1, A Ferro.   

Abstract

Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase. The pathophysiology of heart failure is multi-factorial but recent studies suggest that aldosterone plays an important and independent role in its progression. Emerging evidence now suggests that aldosterone exerts renal-independent effects. It binds to its mineralocorticoid receptor to produce direct effects on the myocardium and vasculature, leading to damaging processes such as hypertrophy, necrosis, fibrosis and endothelial dysfunction, factors known to contribute to the pathophysiology of heart failure. Mineralocorticoid receptor antagonists have thus emerged as a new paradigm for the treatment of heart failure. The benefits of these agents on both morbidity and mortality when used in patients with chronic symptomatic heart failure have been demonstrated by recent trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16846401     DOI: 10.1111/j.1742-1241.2006.00996.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  3 in total

1.  Salivary Gland Dysfunction in Patients with Chronic Heart Failure Is Aggravated by Nitrosative Stress, as Well as Oxidation and Glycation of Proteins.

Authors:  Anna Klimiuk; Anna Zalewska; Małgorzata Knapp; Robert Sawicki; Jerzy Robert Ładny; Mateusz Maciejczyk
Journal:  Biomolecules       Date:  2021-01-18

2.  Red cell distribution width predicts short- and long-term outcomes of acute congestive heart failure more effectively than hemoglobin.

Authors:  Yuxiang Dai; Hakuoh Konishi; Atsutoshi Takagi; Katsumi Miyauchi; Hiroyuki Daida
Journal:  Exp Ther Med       Date:  2014-06-04       Impact factor: 2.447

3.  Efficacy and Safety of 1-Hour Infusion of Recombinant Human Atrial Natriuretic Peptide in Patients With Acute Decompensated Heart Failure: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

Authors:  Guogan Wang; Pengbo Wang; Yishi Li; Wenxian Liu; Shugong Bai; Yang Zhen; Dongye Li; Ping Yang; Yu Chen; Lang Hong; Jianhui Sun; Junzhu Chen; Xian Wang; Jihong Zhu; Dayi Hu; Huimin Li; Tongguo Wu; Jie Huang; Huiqiong Tan; Jian Zhang; Zhongkai Liao; Litian Yu; Yi Mao; Shaodong Ye; Lei Feng; Yihong Hua; Xinhai Ni; Yuhui Zhang; Yang Wang; Wei Li; Xiaojun Luan; Xiaolu Sun; Sijia Wang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.